WO2002022817A3 - Nuclear receptor l66 and methods of use - Google Patents

Nuclear receptor l66 and methods of use Download PDF

Info

Publication number
WO2002022817A3
WO2002022817A3 PCT/EP2001/010323 EP0110323W WO0222817A3 WO 2002022817 A3 WO2002022817 A3 WO 2002022817A3 EP 0110323 W EP0110323 W EP 0110323W WO 0222817 A3 WO0222817 A3 WO 0222817A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuclear receptor
methods
relates
fxr
nucleic acid
Prior art date
Application number
PCT/EP2001/010323
Other languages
French (fr)
Other versions
WO2002022817A2 (en
Inventor
Georg Casari
Michael Hoefer
David Jackson
Harald Kranz
Kerstin Otte
Bettina Remmel
Joerg Suckow
Original Assignee
Lion Bioscience Ag
Georg Casari
Michael Hoefer
David Jackson
Harald Kranz
Kerstin Otte
Bettina Remmel
Joerg Suckow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Bioscience Ag, Georg Casari, Michael Hoefer, David Jackson, Harald Kranz, Kerstin Otte, Bettina Remmel, Joerg Suckow filed Critical Lion Bioscience Ag
Priority to CA002420932A priority Critical patent/CA2420932A1/en
Priority to EP01982261A priority patent/EP1317542A2/en
Priority to AU2002213893A priority patent/AU2002213893A1/en
Publication of WO2002022817A2 publication Critical patent/WO2002022817A2/en
Publication of WO2002022817A3 publication Critical patent/WO2002022817A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a novel nuclear receptor called 'L66' or also FXR-β a homologue of the FXR-α, a prototypical type 2 nuclear receptor. The invention also relates to the isolated nucleic acid sequence of L66 and the isolated protein thereof. The invention further relates to processes for isolating and/or producing the nucleic acid or the protein as well as methods of use of the receptor L66.
PCT/EP2001/010323 2000-09-16 2001-09-07 Nuclear receptor l66 and methods of use WO2002022817A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002420932A CA2420932A1 (en) 2000-09-16 2001-09-07 Novel mammalian nuclear receptor l66 and methods of use
EP01982261A EP1317542A2 (en) 2000-09-16 2001-09-07 Nuclear receptor l66 and methods of use
AU2002213893A AU2002213893A1 (en) 2000-09-16 2001-09-07 Nuclear receptor l66 and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00120370 2000-09-16
EP00120370.2 2000-09-16
EP01111658 2001-05-14
EP01111658.9 2001-05-14

Publications (2)

Publication Number Publication Date
WO2002022817A2 WO2002022817A2 (en) 2002-03-21
WO2002022817A3 true WO2002022817A3 (en) 2003-03-27

Family

ID=26071406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010323 WO2002022817A2 (en) 2000-09-16 2001-09-07 Nuclear receptor l66 and methods of use

Country Status (4)

Country Link
EP (1) EP1317542A2 (en)
AU (1) AU2002213893A1 (en)
CA (1) CA2420932A1 (en)
WO (1) WO2002022817A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109467A1 (en) * 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
WO2003087140A1 (en) * 2002-04-13 2003-10-23 Lion Bioscience Ag NON-PRIMATE FXRb AS A LANOSTEROL SENSING NUCLEAR HORMONE RECEPTOR AND RELATED USES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021677A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Retinoid x receptor-interacting polypeptides and related molecules and methods
US5728548A (en) * 1995-06-29 1998-03-17 Genetics Institute, Inc. Retinoid receptor-1 (RR1) and DNA encoding RR1
US6005086A (en) * 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
WO2000057915A1 (en) * 1999-03-26 2000-10-05 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021677A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Retinoid x receptor-interacting polypeptides and related molecules and methods
US6005086A (en) * 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5728548A (en) * 1995-06-29 1998-03-17 Genetics Institute, Inc. Retinoid receptor-1 (RR1) and DNA encoding RR1
WO2000057915A1 (en) * 1999-03-26 2000-10-05 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] XP002202974, Database accession no. AL358372 *
DATABASE EMBL [online] XP002202975, Database accession no. AA974561 *
HUBER REID M ET AL: "Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.", GENE. NETHERLANDS 15 MAY 2002, vol. 290, no. 1-2, 15 May 2002 (2002-05-15), pages 35 - 43, XP002202973, ISSN: 0378-1119 *
WANG H ET AL: "ENDOGENOUS BILE ACIDS ARE LIGANDS FOR THE NUCLEAR RECEPTOR FXR/BAR", MOLECULAR CELL, CAMBRIDGE, MA, US, vol. 3, May 1999 (1999-05-01), pages 543 - 553, XP000905175, ISSN: 1097-2765 *
WONGI SEOL ET AL: "ISOLATION OF PROTEINS THAT INTERACT SPECIFICALLY WITH THE RETIONOIDX RECEPTOR: TWO NOVEL ORPHAN RECEPTORS", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 9, no. 1, 1995, pages 72 - 85, XP000561076, ISSN: 0888-8809 *

Also Published As

Publication number Publication date
EP1317542A2 (en) 2003-06-11
WO2002022817A2 (en) 2002-03-21
AU2002213893A1 (en) 2002-03-26
CA2420932A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
WO2001079459A3 (en) Polypeptides having haloperoxidase activity
WO2002012501A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
WO2001034646A3 (en) Recombinant gelatins
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
NO20003958L (en) Tumor associated antigen derivatives from the MAGE family, and nucleic acid sequences encoding them, used for the production of fusion proteins and for vaccine compositions
WO2001029222A3 (en) Polypeptides having phospholipase b activity and nucleic acids encoding same
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2003089598A3 (en) Polypeptides having xyloglucanase activity and nucleic acids encoding same
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
CA2167693A1 (en) Melanoma-inhibiting protein
WO2004007664A3 (en) Nucleic acid vectors
AU2001247848A1 (en) Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines
WO2001098469A3 (en) Polypeptides having peroxidase activity and nucleic acids encoding same
WO1997027276A3 (en) Nucleic acids encoding polypeptides having absidia lipase activity
HK1068329A1 (en) Process for the preparation of 2,6-naphthalenedicarboxylic acid
WO2001085762A3 (en) Cancer diagnosis and assays for screening anti-cancer agents
WO2002022817A3 (en) Nuclear receptor l66 and methods of use
WO2000041509A3 (en) Polypeptides having acid phosphatase activity and nucleic acids encoding same
WO1999048851A3 (en) Processes for preparing intermediates
NO20021727L (en) Process for Preparation of 3,4-Methylene Dioxymandelic Acid
ATE253069T1 (en) OPTICALLY PURE CAMPTOTHECINE ANALOGS, OPTICALLY PURE SYNTHESIS INTERMEDIATE PRODUCT AND METHOD FOR THE PRODUCTION THEREOF
WO2002083727A3 (en) Nucleic acid sequences of hyperplasies and tumors of the thyroid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001982261

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2420932

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001982261

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001982261

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP